Inflammatory bowel disease (IBD) is an immune-mediated inflammatory condition of the gastrointestinal tract. Its incidence rose steadily in the last century and the estimated incidence is approximately 2.5 million in Europe and 1.5 million in North America [1]. This condition can be associated with an increased risk of cardiovascular diseases, infections, and cancer [2] The risk of colorectal cancer (CRC) is approximately 2- to 3-fold higher for IBD patients than in the general population. [2] Malignancies are the second most common cause of mortality after cardiovascular disease in patients with IBD.